Resumen: Since hepatitis C virus (HCV) and human T-lymphotropic virus (HTLV) share transmission routes, dual infection could be frequent. In Spain, HTLV underdiagnosis is highlighted by the high proportion of patients presenting either with tropical spastic paraparesis or adult T cell leukemia at first diagnosis. We examined whether the renewed efforts for expanding HCV testing may provide a sentinel population that might selectively be targeted to unveil asymptomatic HTLV carriers. The presence of anti-HTLV antibodies was examined in 3,838 consecutive individuals with reactive HCV serology attended during the last 3 years at 13 hospitals distributed across the Spanish geography. Overall 71% were male, and the median age was 41 years old. Foreigners represented 9% of the study population. A total of 50 individuals (1.3%) were seroreactive for HTLV, being 30 confirmed as HTLV-2 and 2 as HTLV-1 (0.12%). The remaining 18 had indeterminate Western blot patterns. Most individuals with HTLV-2 and HTLV indeterminate serology were human immunodeficiency virus positive, former injection drug users, and native Spaniards. In contrast, the two HTLV-1 infections were found in men coming from Brazil and the Dominican Republic, respectively. In summary, the overall prevalence of HTLV infection in individuals living in Spain seropositive for HCV is 1.3%, more than 10-fold greater than in general outclinics in Spain. However, immigrants from HTLV-1 endemic regions and former injection drug users with HTLV-2 infection are by far the major contributory groups in HCV patients. Therefore, testing for HTLV in newly diagnosed HCV individuals would not contribute much to improve late HTLV diagnosis in Spain. Idioma: Inglés DOI: 10.1089/AID.2016.0323 Año: 2017 Publicado en: AIDS RESEARCH AND HUMAN RETROVIRUSES 54, A (2017), 150-164 ISSN: 0889-2229 Factor impacto JCR: 1.935 (2017) Categ. JCR: INFECTIOUS DISEASES rank: 64 / 88 = 0.727 (2017) - Q3 - T3 Categ. JCR: VIROLOGY rank: 26 / 35 = 0.743 (2017) - Q3 - T3 Categ. JCR: IMMUNOLOGY rank: 128 / 155 = 0.826 (2017) - Q4 - T3 Factor impacto SCIMAGO: 1.066 - Immunology (Q2) - Virology (Q2) - Infectious Diseases (Q2)